Zobrazeno 1 - 10
of 164
pro vyhledávání: '"Markus Falk"'
Autor:
Petros Christopoulos, Franziska Herster, Petra Hoffknecht, Markus Falk, Markus Tiemann, Hans-Georg Kopp, Andre Althoff, Anja Stammberger, Eckart Laack
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) represent first-line standard of care in unresectable EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC). However, 10–20% of patients with EGFRm+ NSCLC have u
Externí odkaz:
https://doaj.org/article/d9d647cfc3ce49f18e8635c29acf8bc3
Autor:
Markus Falk, Stefanie Schatz, Fabian P. M. Reich, Stefanie Schmidt, Marco Galster, Markus Tiemann, Joachim H. Ficker, Wolfgang M. Brueckl
Publikováno v:
Current Oncology, Vol 30, Iss 10, Pp 8865-8871 (2023)
Osimertinib has become the preferred first-line therapy for epidermal growth factor receptor (EGFR) mutation-positive metastatic non-small cell lung cancer (NSCLC) in recent years. Originally, it was approved for second-line treatment after epidermal
Externí odkaz:
https://doaj.org/article/b7c8a890c708457da0e9fd83917a7c0e
Autor:
Balázs Jóri, Christine Vössing, Judith Pirngruber, Eva Maria Willing, Kathrin Arndt, Markus Falk, Markus Tiemann, Lukas C. Heukamp, Petra Hoffknecht
Publikováno v:
Current Oncology, Vol 30, Iss 10, Pp 8805-8814 (2023)
EGFR-mutant lung cancers develop a wide range of potential resistance alterations under therapy with the third-generation EGFR tyrosine kinase inhibitor osimertinib. MET amplification ranks among the most common acquired resistance alterations and is
Externí odkaz:
https://doaj.org/article/4e628e918b044546be96ca670e533995
Publikováno v:
Biomedicines, Vol 12, Iss 3, p 688 (2024)
Background: The PACIFIC study showed that after radio-chemotherapy, patients with NSCLC derived a benefit in PFS and OS when treated with durvalumab. This effect was limited to patients with a PD-L1 expression of >1%, partly because the outcome in th
Externí odkaz:
https://doaj.org/article/132259ff97574f71b547049680204213
Autor:
Markus Falk, Eva Willing, Stefanie Schmidt, Stefanie Schatz, Marco Galster, Markus Tiemann, Joachim H. Ficker, Wolfgang M. Brueckl
Publikováno v:
Current Oncology, Vol 30, Iss 2, Pp 1692-1698 (2023)
HER2-targeted therapy is currently the subject of several studies in lung cancer and other solid tumors using either tyrosine kinase inhibitors (TKI) or targeted-antibody–drug conjugates. We describe a 61-year-old female patient with HER2 mutated a
Externí odkaz:
https://doaj.org/article/bfd2ba978067494890b7d43b5150ef0a
Autor:
Balázs Jóri, Markus Falk, Iris Hövel, Peggy Weist, Markus Tiemann, Lukas C. Heukamp, Frank Griesinger
Publikováno v:
Current Oncology, Vol 29, Iss 9, Pp 6628-6634 (2022)
Lorlatinib, a third-generation anaplastic lymphoma kinase (ALK)/receptor tyrosine kinase inhibitor (ROS1), demonstrated efficacy in ROS1 positive (ROS1+) non-small cell lung cancer (NSCLC), although approval is currently limited to the treatment of A
Externí odkaz:
https://doaj.org/article/01713b1bc883416682ca8dad6191d905
Autor:
Eva-Maria Willing, Claudia Vollbrecht, Christine Vössing, Peggy Weist, Simon Schallenberg, Johanna M. Herbst, Stefanie Schatz, Balázs Jóri, Guillaume Bataillon, Philipp Harter, Vanda Salutari, Antonio Gonzáles Martin, Ignace Vergote, Nicoletta Colombo, Julia Roeper, Tobias Berg, Regina Berger, Bettina Kah, Trine Jakobi Noettrup, Markus Falk, Kathrin Arndt, Andreas Polten, Isabelle Ray-Coquard, Franziska Selzam, Judith Pirngruber, Stefanie Schmidt, Michael Hummel, Markus Tiemann, David Horst, Jalid Sehouli, Eric Pujade-Lauraine, Katharina Tiemann, Elena Ioana Braicu, Lukas C. Heukamp
Publikováno v:
Cancers, Vol 15, Iss 13, p 3445 (2023)
The worldwide approval of the combination maintenance therapy of olaparib and bevacizumab in advanced high-grade serous ovarian cancer requires complex molecular diagnostic assays that are sufficiently robust for the routine detection of driver mutat
Externí odkaz:
https://doaj.org/article/628b6ba5d10e423992d704d588ad94ad
Autor:
Bernd Wallner, Luca Moroder, Hannah Salchner, Peter Mair, Stefanie Wallner, Gabriel Putzer, Giacomo Strapazzon, Markus Falk, Hermann Brugger
Publikováno v:
Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, Vol 29, Iss 1, Pp 1-8 (2021)
Abstract Background The aim of this manikin study was to evaluate the quality of cardiopulmonary resuscitation (CPR) with restricted patient access during simulated avalanche rescue using over-the-head and straddle position as compared to standard po
Externí odkaz:
https://doaj.org/article/43d2e4a275e8432b89ddab2a71d9454d
Autor:
Bernd Wallner, Bettina Schenk, Peter Paal, Markus Falk, Giacomo Strapazzon, Wenjun Z. Martini, Hermann Brugger, Dietmar Fries
Publikováno v:
Frontiers in Physiology, Vol 13 (2022)
Introduction: This experimental in vitro study aimed to identify and characterize hypothermia-associated coagulopathy and to compare changes in mild to severe hypothermia with the quantitative measurement of rotational thromboelastometry (ROTEM) and
Externí odkaz:
https://doaj.org/article/35b6082f73d74598a3eacb071eb393b0
Autor:
Svenja Wagener-Ryczek, Carina Heydt, Juliane Süptitz, Sebastian Michels, Markus Falk, Christina Alidousty, Jana Fassunke, Michaela Angelika Ihle, Markus Tiemann, Lukas Heukamp, Jürgen Wolf, Reinhard Büttner, Sabine Merkelbach-Bruse
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-11 (2020)
Abstract Background Over the past years, EGFR tyrosine kinase inhibitors (TKI) revolutionized treatment response. 1st-generation (reversible) EGFR TKI and later the 2nd –generation irreversible EGFR TKI Afatinib were aimed to improve treatment resp
Externí odkaz:
https://doaj.org/article/f7936ba47ab04f9d9e1b464f58d1640a